Spero Therapeutics Inc (SPRO) - Net Assets
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has net assets worth $26.49 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($54.17 Million) and total liabilities ($27.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SPRO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.49 Million |
| % of Total Assets | 48.91% |
| Annual Growth Rate | N/A |
| 5-Year Change | -65.07% |
| 10-Year Change | N/A |
| Growth Volatility | 410.19 |
Spero Therapeutics Inc - Net Assets Trend (2015–2024)
This chart illustrates how Spero Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore SPRO current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Spero Therapeutics Inc (2015–2024)
The table below shows the annual net assets of Spero Therapeutics Inc from 2015 to 2024. For live valuation and market cap data, see SPRO market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $46.12 Million | -56.85% |
| 2023-12-31 | $106.89 Million | +40.77% |
| 2022-12-31 | $75.93 Million | -13.99% |
| 2021-12-31 | $88.29 Million | -33.13% |
| 2020-12-31 | $132.04 Million | +77.06% |
| 2019-12-31 | $74.57 Million | -35.63% |
| 2018-12-31 | $115.86 Million | +36.37% |
| 2017-12-31 | $84.96 Million | +1235.59% |
| 2016-12-31 | $6.36 Million | +2575.10% |
| 2015-12-31 | $-257.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Spero Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44153800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00K | 0.12% |
| Other Components | $505.71 Million | 1096.43% |
| Total Equity | $46.12 Million | 100.00% |
Spero Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Spero Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
$132.96 Million |
|
Prosafe SE
OL:PRS
|
$132.99 Million |
|
UBM Development AG
VI:UBS
|
$133.00 Million |
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
$133.03 Million |
|
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KQ:307750
|
$132.95 Million |
|
Peninsula Energy Ltd
AU:PEN
|
$132.91 Million |
|
Bank Mnc Internasional Tbk
JK:BABP
|
$132.86 Million |
|
Fortinova Fastigheter AB Series B
ST:FNOVA-B
|
$132.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spero Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 106,894,000 to 46,123,000, a change of -60,771,000 (-56.9%).
- Net loss of 68,566,000 reduced equity.
- Other factors increased equity by 7,795,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.57 Million | -148.66% |
| Other Changes | $7.79 Million | +16.9% |
| Total Change | $- | -56.85% |
Book Value vs Market Value Analysis
This analysis compares Spero Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 83.57x to 2.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.03 | $2.48 | x |
| 2016-12-31 | $1.54 | $2.48 | x |
| 2017-12-31 | $32.84 | $2.48 | x |
| 2018-12-31 | $7.24 | $2.48 | x |
| 2019-12-31 | $4.11 | $2.48 | x |
| 2020-12-31 | $5.90 | $2.48 | x |
| 2021-12-31 | $2.86 | $2.48 | x |
| 2022-12-31 | $2.02 | $2.48 | x |
| 2023-12-31 | $2.02 | $2.48 | x |
| 2024-12-31 | $0.85 | $2.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spero Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -148.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -142.91%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 2.40x
- Recent ROE (-148.66%) is above the historical average (-595.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -5180.61% | 0.00% | 0.00x | 36.61x | $-10.17 Million |
| 2016 | -250.67% | -7609.25% | 0.02x | 1.35x | $-26.51 Million |
| 2017 | -54.26% | -2329.31% | 0.02x | 1.10x | $-54.59 Million |
| 2018 | -35.96% | -1050.48% | 0.03x | 1.11x | $-53.25 Million |
| 2019 | -80.69% | -1268.98% | 0.04x | 1.42x | $-67.63 Million |
| 2020 | -58.71% | -830.86% | 0.06x | 1.16x | $-90.72 Million |
| 2021 | -101.66% | -2923.65% | 0.02x | 1.94x | $-98.58 Million |
| 2022 | -61.13% | -95.55% | 0.39x | 1.64x | $-54.01 Million |
| 2023 | 21.34% | 21.98% | 0.57x | 1.71x | $12.12 Million |
| 2024 | -148.66% | -142.91% | 0.43x | 2.40x | $-73.18 Million |
Industry Comparison
This section compares Spero Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spero Therapeutics Inc (SPRO) | $26.49 Million | -5180.61% | 1.04x | $132.96 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more